Stockwatch: Politics And Profits May Pollute Pharma’s Pandemic Response
Vaccine Nationalism And Financial Imperatives Generate Friction
It is hard enough speeding novel vaccines against novel pathogens to global markets whilst balancing profit imperatives with societal benefit. Political interventions have the potential to introduce additional friction.
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.